BridgeBio Oncology and Helix Acquisition Announce Merger to Create Biotech Company BridgeBio Oncology Therapeutics (BBOT), a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for RAS and PI3Kα-targeted…
Compass Pathways Reports Q4 and Full-Year 2024 Financial Results Compass Pathways plc (Nasdaq: CMPS), a leading biotechnology company focused on advancing mental health treatment, has announced its financial results for…
eClinicalWorks and healow Genie to Enhance Patient Experience for Largest Neurology Practice eClinicalWorks®, the largest ambulatory cloud EHR provider, has announced that First Choice Neurology, Florida’s largest neurology practice with…
Demetra Holding Acquires Majority Stake in GetSet Surgical, Expanding Spine Portfolio Demetra Holding, a global leader in providing anti-infective cements, spacers, and biomaterials for orthopedic applications, has announced the acquisition…
MEDITECH Genomics Integration Boosts Targeted Cancer Care at Frederick Health Frederick Health (Frederick, MD) has introduced a groundbreaking precision medicine integration aimed at enhancing decision support with personalized recommendations based…
RDD Europe 2025 Celebrates 20 Years, Co-Organized by Aptar Pharma and RDD Online Aptar Pharma, a global leader in respiratory drug delivery solutions, and RDD Online® are proud to announce…
ImmunoPrecise Antibodies Announces Restructuring of Management Team ImmunoPrecise Antibodies (IPA) (NASDAQ: IPA), an AI-driven biotherapeutics discovery and technology company, is excited to share several important leadership changes. Kamil Isaev has…
Healx Doses First Patient in Phase 2 Trial of HLX-1502 for Neurofibromatosis Type 1 Healx, a clinical-stage biotech company utilizing AI to advance treatments for rare diseases, has announced that…
PepGen Announces Positive Results from FREEDOM-DM1 Trial in DM1 Patients PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company focused on advancing next-generation oligonucleotide therapies, recently announced promising early results from…
FDA Accepts Bristol Myers Squibb’s Application for Opdivo® + Yervoy® in MSI-High or MMR-Deficient Cancer Bristol Myers Squibb (NYSE: BMY) recently announced that the U.S. Food and Drug Administration (FDA)…
Almirall 2024 Results: Surpasses Guidance, Poised for Sustained Growth Almirall, S.A., a global biopharmaceutical company based in Barcelona, has reported strong financial results for the full year of 2024. The…
Triastek’s D23 (Budesonide Ileum-Targeted Tablet) Shows Positive Clinical Results Triastek has announced that its 3D-printed drug, D23 (Budesonide Ileum-Targeted Tablet), has achieved positive results in a recent clinical trial aimed…